Cargando…

Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis

OBJECTIVE: Biologic drug therapies represent a huge advance in the treatment of rheumatoid arthritis (RA). However, very good disease control is achieved in only 30% of patients, making identification of biomarkers of response a research priority. We undertook this study to test our hypothesis that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Plant, Darren, Webster, Amy, Nair, Nisha, Oliver, James, Smith, Samantha L., Eyre, Steven, Hyrich, Kimme L., Wilson, Anthony G., Morgan, Ann W., Isaacs, John D., Worthington, Jane, Barton, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914881/ https://www.ncbi.nlm.nih.gov/pubmed/26814849 http://dx.doi.org/10.1002/art.39590

Ejemplares similares

Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis
por: Smith, Samantha Louise, et al.
Publicado: (2023)

Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2019)

Genome-Wide Association Study of Genetic Predictors of Anti–Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations with Polymorphisms at Seven Loci
por: Plant, Darren, et al.
Publicado: (2011)

Replication of Association of the PTPRC Gene With Response to Anti–Tumor Necrosis Factor Therapy in a Large UK Cohort
por: Plant, Darren, et al.
Publicado: (2012)

Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis
por: Cordingley, Lis, et al.
Publicado: (2014)

Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes
por: Hope, Holly F, et al.
Publicado: (2016)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis: Implications for Causal Gene Identification
por: Thalayasingam, Nishanthi, et al.
Publicado: (2018)

Novel Rheumatoid Arthritis Susceptibility Locus at 22q12 Identified in an Extended UK Genome-Wide Association Study
por: Orozco, Gisela, et al.
Publicado: (2014)

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
por: Low, Audrey S. L., et al.
Publicado: (2016)

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2012)

No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
por: Lunt, Mark, et al.
Publicado: (2010)

Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage
por: Gallo, G, et al.
Publicado: (2016)

Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response
por: Cherlin, Svetlana, et al.
Publicado: (2020)

Impact of etanercept tapering on work productivity in patients with early rheumatoid arthritis: results from the PRIZE study
por: Zhang, Wei, et al.
Publicado: (2016)

Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis
por: Tao, Weiyang, et al.
Publicado: (2020)

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population
por: Mercer, Louise K., et al.
Publicado: (2013)

Etanercept‐Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis
por: Bonafede, Machaon, et al.
Publicado: (2015)

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39
por: Spiliopoulou, Athina, et al.
Publicado: (2019)

Brief Report: Identification of BACH2 and RAD51B as Rheumatoid Arthritis Susceptibility Loci in a Meta-Analysis of Genome-Wide Data
por: McAllister, Kate, et al.
Publicado: (2013)

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
por: Matucci-Cerinic, Marco, et al.
Publicado: (2018)

The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort
por: Smith, Samantha Louise, et al.
Publicado: (2017)

Replication of Associations of Genetic Loci Outside the HLA Region With Susceptibility to Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis
por: Viatte, Sebastien, et al.
Publicado: (2016)

Estimating the monetary value of the annual productivity gained in patients with early rheumatoid arthritis receiving etanercept plus methotrexate: interim results from the PRIZE study
por: Zhang, Wei, et al.
Publicado: (2015)

Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
por: Jani, Meghna, et al.
Publicado: (2019)

Genetics of RA susceptibility, what comes next?
por: Ding, James, et al.
Publicado: (2015)

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
por: Emery, Paul, et al.
Publicado: (2020)

Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis: Implications for Understanding Preclinical Rheumatoid Arthritis
por: de Hair, MJH, et al.
Publicado: (2014)

Association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review
por: Dey, Mrinalini, et al.
Publicado: (2022)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

Glucocorticoids and chronotherapy in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2016)

Management of Fatigue in Rheumatoid Arthritis
por: Pope, Janet E
Publicado: (2020)

Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming
por: Cooles, Faye A H, et al.
Publicado: (2022)

Biologicals in rheumatoid arthritis: current and future
por: Avci, Ali Berkant, et al.
Publicado: (2015)

Don’t neglect nutrition in rheumatoid arthritis!
por: Cutolo, Maurizio, et al.
Publicado: (2018)

Rheumatoid arthritis prevention: any takers?
por: Falahee, Marie, et al.
Publicado: (2021)

Overtreatment in rheumatoid arthritis: are there reasons for concern?
por: Ferreira, Ricardo J O, et al.
Publicado: (2022)

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2014)

Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals
por: Kroese, Johanna M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6409kp40ueuuafvvp53a8qi6mj